Click here for the replay of "Myeloma 101 - Updates on Treatment & Pain Management" teleconference
IMF Chairman Dr. Brian Durie will present “Myeloma 101: Updates on Treatment & Pain Management ” during this informative teleconference, and will shed light on the most up-to-date therapies for myeloma patients. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 19, 2015 Category: Hematology Source Type: news
Click here for the replay of "Myeloma 101 - Updates on Treatment & Pain Management" teleconference
IMF Chairman Dr. Brian Durie will present “Myeloma 101: Updates on Treatment & Pain Management” during this informative teleconference, and will shed light on the most up-to-date therapies for myeloma patients. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 19, 2015 Category: Hematology Source Type: news
European Commission Approves Kyprolis & #174; (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
First Irreversible Proteasome Inhibitor for Relapsed Multiple Myeloma Approved in the European Union. Approval Based on Data From Pivotal Phase 3 ASPIRE Trial Which Demonstrated Patients Treated With Kyprolis in Combination Lived Nearly Nine Months Longer Without Disease Progression Compared to Common Treatment Course. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 18, 2015 Category: Hematology Source Type: news
European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
First Irreversible Proteasome Inhibitor for Relapsed Multiple Myeloma Approved in the European Union. Approval Based on Data From Pivotal Phase 3 ASPIRE Trial Which Demonstrated Patients Treated With Kyprolis in Combination Lived Nearly Nine Months Longer Without Disease Progression Compared to Common Treatment Course. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 18, 2015 Category: Hematology Source Type: news
Great news for myeloma patients: FDA approves daratumumab
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 16, 2015 Category: Hematology Source Type: news
Black Swan Research Initiative Continues to Take the Stage for Advances in Myeloma
n his blog this week, IMF Chairman Dr. Brian Durie reports on last week's symposium on “New Developments in MRD Diagnostics,” held in Zurich, Switzerland by the ESLHO (European Scientific Foundation of Laboratory Hemato Oncology). Conference panelists included Dr. Durie, who discussed MRD (minimal residual disease) and its role in the IMF's signature Black Swan Research Initiative (BSRI), and fellow BSRI investigators Drs. Alberto Orfao (in photo) and Bruno Paiva. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 13, 2015 Category: Hematology Source Type: news
Watch the replay of the "Multiple Myeloma and VA Benefits" webinar
Learn more about strategies for veteran's to maxmize access to VA support with Raymond Gustavson, a Retired Rating Specialist (RVSR) on the VA Appeals team. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 12, 2015 Category: Hematology Source Type: news
Download the slides for tonight's "Multiple Myeloma and VA Benefits"
Learn more about strategies for veteran's to maxmize access to VA support with Raymond Gustavson, a Retired Rating Specialist (RVSR) on the VA Appeals team. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 12, 2015 Category: Hematology Source Type: news
The Bad and the Good About Food, Cancer, and Longevity
In his blog this week, IMF Chairman Dr. Brian Durie discusses the media frenzy surrounding The World Health Organization (WHO) study that proposed red and processed meats could be linked to cancer. The WHO and its linked research group, the International Agency for Research on Cancer (IARC) classified bacon and hot dogs as “human carcinogens (Group 1).” That designation means they are causing cancer in the same way that tobacco and asbestos are classified as cancer-causing agents. There is more to this story than just the headlines however, and Dr. Durie explains more about what this study means HERE. (Source: Internat...
Source: International Myeloma Foundation - November 7, 2015 Category: Hematology Source Type: news
International Myeloma Foundation Scores Support in Takeda Oncology's ‘3 Points for Patients' Campaign Partnership with NBA's Boston Celtics
< p > Every 3-Point Basket Will Trigger a Donation for IMF Research and Education < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 5, 2015 Category: Hematology Source Type: news
International Myeloma Foundation Scores Support in Takeda Oncology's
‘3 Points for Patients' Campaign Partnership with NBA's Boston Celtics
Every 3-Point Basket Will Trigger a Donation for IMF Research and Education (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 5, 2015 Category: Hematology Source Type: news
IMF Builds Exciting New Collaborations in China
In his blog this week, IMF Chairman Dr. Brian Durie recaps the IMF team's trip last week to China. “The future is definitely bright for new developments in China,” he writes. “There are many challenges, including access to care and costs, but there is a strong commitment to do the very best for patients with resources available.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 29, 2015 Category: Hematology Source Type: news
Is There Value or Risk in New Guidance on Myeloma Treatment?
In his blog, IMF Chairman Dr. Brian Durie comments on the myeloma treatment guidance issued last week by the National Comprehensive Cancer Network (NCCN). The NCCN says its “evidence blocks” approach will provide a tool to educate providers and patients about “efficacy, safety, and affordability” of treatments. It is just one of several recent efforts to evaluate and recommend specific cancer treatment paths. Dr. Durie weighs in on the relative merits and drawbacks of these efforts. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 26, 2015 Category: Hematology Source Type: news
Myeloma Patient Registered to Run His 90th Marathon with Cancer
Don Wright didn't let his 2003 myeloma diagnosis stop him in tracks. This weekend, Don is registered to run his 90th marathon with myeloma in Washington, D.C. The 74-year old says he's managed his cancer for seven of the last twelve years with oral cancer therapies, but knows “multiple myeloma cannot be cured, so I am counting on continuing progress, research and access to the latest treatments to provide the next remission and the remission after that.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 23, 2015 Category: Hematology Source Type: news
Register now for the Clinical Pathways webinar on Wednesday Nov. 11
Please join the IMF Advocacy team on Wednesday, November 11 at 7:00 PM EST, for a special presentation on Clinical Pathways. Pathways are a mechanism used by insurers to make health care costs more predictable by prescribing a course of treatment in which the type and timing of specific therapies are pre-determined. The presentation will go over how pathways are developed, so that you can make more informed decisions about your care. It will also cover how to talk to your physician about how these pathways are structured within their practices and whether they have placed you on a particular pathway. We hope to see you th...
Source: International Myeloma Foundation - October 22, 2015 Category: Hematology Source Type: news
